[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dystonia-secondary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dystonia-secondary":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100558681","phase-1-pharmacogenomic-contributions-to-trihexyphenidyl-biotransformation-and-response-in-children-with-dystonic-cerebral-palsy-100558681",false,"NCT06554288","Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy","Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy","TRIKE2","Inclusion Criteria:\n\n* Ages 5-17 years of age\n* Diagnosis of cerebral palsy and dystonia causing interference\n* Parent\u002Flegal guardian of a child with a diagnosis of cerebral palsy and dystonia\n* Parent\u002Flegal guardian is willing and able to provide informed permission\u002Fassent for the study\n\nExclusion Criteria:\n\n* Previously or currently taking trihexyphenidyl\n* Patients turning 18 years of age within the study period (16 weeks from Study Day 1)\n* A language barrier for the patient that precludes communication and\u002For the ability to complete study-related requirements","ALL","5 Years","17 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.",[28,29,30,31,32,33,34,35],"Pediatric Disorder","Genetic Predisposition","Dystonia, Secondary","Dystonia","Cerebral Palsy, Dystonic-Rigid","Cerebral Palsy, Dyskinetic","Trihexyphenidyl Adverse Reaction","Pharmacogenomic Drug Interaction",[37,38,31,39,40],"Pediatric","Cerebral Palsy","Pharmacogenomics","Trihexyphenidyl","RECRUITING","2026-06-19",{"date":44,"type":45},"2026-06-24","ACTUAL",{"date":47,"type":45},"2024-10-15",{"date":49,"type":22},"2029-12-31",{"name":51,"class":52},"Children's Mercy Hospital Kansas City","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":88,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":53},"100318611","dystonia-genotype-phenotype-correlation-100318611","NCT03428009","Dystonia Genotype-Phenotype Correlation","Dystonia Genotype-Phenotype Correlation: A Study to Identify Additional Genetic Associations That Contribute to Specific Dystonic Phenotypes","General Exclusion (both Dystonia and Control groups):\n\n* Metal in any part of the body (including metal injury to the eye) OR carrying a medical device incompatible with MRI (e.g., metal implants such as surgical clips or pacemakers) OR positive screening per UTSW MRI screening form\n* Claustrophobia\n* Non-fluent English\n* Weight incompatible with MRI safety\n* History of head trauma with neurological sequelae, including multiple concussions and\u002For history of stroke\n* Pregnancy\n* Serious medical illness or history of serious medical illness, including cancer that was treated with radiation or chemotherapy, heart attack, or a known history of HIV-1 + status\n* Subjects with Hepatitis C (by Hepatitis C+ titer)\n* Subjects with insulin dependent diabetes mellitus (IDDM)\n* Severe respiratory compromise\n* In the opinion of the investigator, not able to safely participate in this study\n\nInclusion Criteria:\n\n* Dystonia group\n\nPrevious diagnosis of dystonia which include but is not limited to:\n\n* cervical dystonia (50 subjects)\n* blepharospasm (25 subjects)\n* limb dystonia (50 subjects)\n* spasmodic dysphonia (25 subjects)\n* segmental dystonia\n* multi-focal dystonia\n* Any childhood-onset dystonia (25 subjects) Age \\> 11 years\n\n  * Control group:\n\nNo prior dystonia diagnosis (175 subjects) Age \\> 11 years\n\nExclusion Criteria:\n\n* Dystonia group Prior history of or concurrent neurological or psychiatric diagnosis - depression and\u002For anxiety accepted Current use of non-dystonia neuroactive medications - SSRI\u002Fmedication for depression and\u002For anxiety accepted Current use of cervical brace designed for dystonia treatment Prior structural brain injury\n\nControl group:\n\nHistory of or current neurological or psychiatric diagnosis - depression and\u002For anxiety accepted, but must not be in active phase Current use of any neuroactive medication, SSRI\u002Fmedication for depression and\u002For anxiety accepted",true,"11 Years",{"count":64,"type":22},200,"OBSERVATIONAL","The purpose of this study is to (1) investigate the effect of known dystonia-causing mutations on brain structure and function, to (2) identify structural brain changes that differ between clinical phenotypes of dystonia, and to (3) collect DNA, detailed family history, and clinical phenotypes from patients with idiopathic dystonia with the goal of identifying new dystonia-related genes. Investigators will be recruiting both healthy control subjects and subjects with any form of dystonia. For this study there will be a maximum of two study visit involving a clinical assessment, collection of medical and family history, task training session, an MRI using the learned tasks, and finally a blood draw for genetic analysis. In total, these visits will take 3-5 hours. If the dystonia subjects receive botulinum toxin injections for treatment, the participants and their matched controls will be asked to come for a second visit.",[31,68,69,30,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87],"Dystonia; Idiopathic","Dystonia, Primary","Dystonia, Familial","Dystonia Disorder","Dystonias, Sporadic","Dystonia; Orofacial","Dystonia Lenticularis","Dystonia, Paroxysmal","Dystonia 6","Dystonia 5","Dystonia 8","Dystonia 9","Dystonia 19","Dystonia 10","Dystonia 11","Dystonia 20","Dystonia 12","Dystonia, Focal","Dystonia of Head","Dystonia, Diurnal",[31,89,90,91,92],"Control","Magnetic Resonance Imagine","Genotype","Phenotype","2025-06-03",{"date":95,"type":45},"2025-06-06",{"date":97,"type":45},"2018-03-01",{"date":99,"type":22},"2027-09",{"name":101,"class":52},"University of Texas Southwestern Medical Center",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100486314","enhancing-sensorimotor-processing-in-children-with-dystonia-100486314","NCT05612464","Enhancing Sensorimotor Processing in Children With Dystonia","Enhancing Cortical Sensorimotor Processing in Children\u002FYoung People With Dystonia and Dystonic Cerebral Palsy - An Observational Study to Evaluate Whether Neurofeedback Can Enhance Modulation of the mu Brain Rhythm in Children and Young People With Dystonia\u002FDystonic Cerebral Palsy","Key inclusion criteria\n\nControl Group:\n\n* Age 5 -25 years\n* No known disorder of movement\n* Able to understand and participate in study.\n\nPrimary dystonia group (isolated genetic or idiopathic):\n\n* Age 5-25 years\n* Clinical dystonia - as confirmed on clinical assessment by consultant paediatric neurologist.\n* Genetic or idiopathic aetiology.\n* No other neurological abnormality.\n* Normal cranial magnetic resonance imaging (MRI).\n* Able to understand and participate in study.\n\nDystonic Cerebral Palsy Group:\n\n* Age 5-25 years\n* Clinical dystonia\u002Fdyskinesia - as confirmed on clinical assessment by consultant paediatric neurologist.\n* Documented history of perinatal hypoxic-ischaemic encephalopathy (HIE), prematurity \\\u003C35 weeks or kernicterus.\n* Predominant dystonia\u002Fdyskinesia \u002F Minimal spasticity\n* MRI findings in keeping with acute perinatal HIE, prematurity or kernicterus (including classical pattern of damage to thalami, basal ganglia and peri-rolandic cortex, periventricular leukomalacia or ischaemic parenchymal injury).\n* Able to understand and participate in study.\n\nKey exclusion criteria\n\nControl Group:\n\n* Age \\\u003C5 or \\>25 years\n* Any known disorder of movement.\n\nPrimary dystonia group (isolated genetic or idiopathic):\n\n* Age \\\u003C 5 or \\>25 years\n* Presence of other neurological abnormality in addition to dystonia.\n* Abnormal cranial MRI.\n\nDystonic Cerebral Palsy Group:\n\n* Age \\\u003C 5 or \\>25 years\n* No clear history of perinatal HIE, prematurity or kernicterus.\n* Predominant spasticity.\n* MRI scan not compatible with perinatal HIE, prematurity or kernicterus","25 Years",{"count":111,"type":22},90,"Dystonia is a severely disabling movement disorder with no cure, in which people suffer painful muscle spasms causing twisting movements and abnormal postures. There are many causes, including genetic conditions and brain injury. The most common cause in childhood is dystonic cerebral palsy (CP) which often affects the whole body.\n\nThe underlying mechanisms are unknown, but there is growing evidence to implicate abnormal brain processing by the brain of incoming \"sensory\" information (e.g., signals to the brain from our senses of touch and body position): the distorted perception of these signals disrupts the way the brain produces instructions for planning and performing movements.\n\nThe investigator's previous studies have shown that the way the brain processes sensory information related to movement is abnormal in children with dystonia and dystonic CP, by using methods that record the EEG (electroencephalogram - brain wave signals) and\u002For EMG (electromyogram - electrical signal from muscles). A specific brain rhythm (called mu) typically shows well-defined changes in response to movement, and reflects processing of sensory information. The investigator's work shows these rhythm changes are abnormal in children with dystonia\u002Fdystonic CP.\n\nThis study will explore if these findings can improve treatment. In particular the study team will investigate whether children and young people with dystonia\u002Fdystonic CP can enhance these mu rhythm responses during a movement task by using feedback of their brain rhythms displayed as a cartoon\u002Fgame on a computer. The investigators will also assess whether enhanced mu activity is associated with improved movement control. This would open future possibilities to use such devices for therapy\u002Frehabilitation.\n\nChildren and young people with dystonia\u002Fdystonic CP aged 5-25 years will be recruited, along with age-matched controls. Studies will last 2-3 hours with time for breaks and will be conducted at Evelina London Children's Hospital and Barts Health Trust, with the option for home visits if preferable for families.",[31,114,30,69,68],"Dystonic Cerebral Palsy","NOT_YET_RECRUITING","2022-11-09",{"date":118,"type":45},"2022-11-10",{"date":120,"type":22},"2023-02-01",{"date":122,"type":22},"2028-02-01",{"name":124,"class":52},"King's College London"]